Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-15 armored anti-CD19 CAR-NK cells
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**IL-15 armored anti-CD19 CAR-NK cells** are allogeneic natural killer (NK) cells, typically derived from cord blood units, genetically engineered to express a chimeric antigen receptor (CAR) targeting **CD19** on B-cell malignancies and secreting **interleukin-15 (IL-15)** or IL-15/IL-15Rα to enhance persistence, proliferation, and cytotoxicity. The CAR provides specific tumor recognition and activation via CD19 binding, while IL-15 autocrine signaling promotes NK cell survival, metabolic fitness, and resistance to exhaustion independent of exogenous cytokines. Developed by researchers at **MD Anderson Cancer Center**, this off-the-shelf cell therapy has demonstrated a **73% response rate** in relapsed/refractory B-cell malignancies like chronic lymphocytic leukemia (CLL) and lymphoma in a phase 1/2 trial (NCT03056339), with favorable safety (no cytokine release syndrome or neurotoxicity) and superior antitumor activity in preclinical models compared to non-armored CAR-NK cells[3][10].
- Other names
- CAR19/IL-15 NK cellsiC9/CAR.19/IL15 NK cellsCAR.19-IL15
02
Targets
CD19 (B lymphocyte antigen CD19)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on IL-15 armored anti-CD19 CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-15 armored anti-CD19 CAR-NK cells.